Trial Profile
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications Chikungunya virus infections; COVID 2019 infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 Feb 2023 Status changed from active, no longer recruiting to completed.
- 02 Feb 2023 Planned End Date changed from 18 Apr 2023 to 15 Feb 2023.
- 02 Feb 2023 Planned primary completion date changed from 7 Apr 2023 to 10 Feb 2023.